Suchergebnisse - "Li, Cheryl"

PubPharm (84)

1

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

2

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer Medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

3

DUAL ANTAGONIST AND USE THEREOF

enthalten in: Europäisches Patentamt | 2023

von MA JI | GAO YUN | LI CHERYL XIUYAN | +5

4

Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

enthalten in: Journal of clinical pharmacology | 2023

von Li, C. | Watson, K. | Wang, S. | +2

5

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

enthalten in: Haematologica | 2023

von Pratz, K. | Kaplan, J. | Levy, M. | +16

6

Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

enthalten in: The Journal of Clinical Pharmacology | 2023

von Li, C. | Watson, K. | Wang, S. | +2

7

Neuronal HSF-1 coordinates the propagation of fat desaturation across tissues to enable adaptation to high temperatures in C. elegans

enthalten in: PLoS biology | 2021

von Chauve, L. | Hodge, F. | Murdoch, S. | +14

8

Obesity protects against sepsis-induced and norepinephrine-induced white adipose tissue browning

enthalten in: American journal of physiology. Endocrinology and metabolism | 2021

von Li, C. | Davis, X. | Lahni, P. | +3

9

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

enthalten in: Cancer chemotherapy and pharmacology | 2020

von Li, C. | Sweeney, K. | Cronenberger, C.

10

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

enthalten in: Arthritis research & therapy | 2019

von Danto, S. | Shojaee, N. | Singh, R. | +4

1
2
3
4
5
6
7
8
9
Nächster »
[9]